Rani Therapeutics Holdings (RANI) Operating Leases (2022 - 2026)
Rani Therapeutics Holdings (RANI) posted quarterly Operating Leases of $2.5 million for Q1 2026, down 27.52% year-over-year from $3.4 million in Q1 2025, and down 9.19% quarter-over-quarter from $2.7 million in Q4 2025.
Rani Therapeutics Holdings (RANI) Operating Leases (2022 - 2026) Analysis & Trends
Rani Therapeutics Holdings' Operating Leases history runs 5 years deep, the most recent figure standing at $2.5 million for Q1 2026.
- In Q1 2026, Operating Leases fell 27.52% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $2.5 million (down 27.52% YoY), while the FY2025 annual figure was $2.7 million, down 24.88% from the prior year.
- Operating Leases for Q1 2026 stood at $2.5 million, down from $2.7 million in the prior quarter.
- The five-year high for Operating Leases was $4.7 million in Q1 2024, with the low at $59000.0 in Q4 2022.
- The 5-year median for Operating Leases is $2.6 million (2025), against an average of $2.1 million.
- The sharpest annual moves came in 2023 and 2024: Operating Leases slumped 46.23% in 2023, then surged 2249.12% in 2024.
- Rani Therapeutics Holdings' Operating Leases stood at $59000.0 in 2022, then surged by 189.83% to $171000.0 in 2023, then soared by 2026.9% to $3.6 million in 2024, then decreased by 24.88% to $2.7 million in 2025, then dropped by 9.19% to $2.5 million in 2026.
- Business Quant data shows RANI's Operating Leases at $2.5 million in Q1 2026, $2.7 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn |
| 10 | Rani Therapeutics Holdings | 160.33 Mn | 160.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.22 Mn |
| Mar 31, 2026 | 2.48 Mn |
| Dec 31, 2025 | 2.73 Mn |
| Sep 30, 2025 | 2.97 Mn |
| Jun 30, 2025 | 3.20 Mn |
| Mar 31, 2025 | 3.42 Mn |
| Dec 31, 2024 | 3.64 Mn |
| Sep 30, 2024 | 4.02 Mn |
| Jun 30, 2024 | 4.39 Mn |
| Mar 31, 2024 | 4.75 Mn |
| Sep 30, 2023 | 171,000.00 |
| Jun 30, 2023 | 338,000.00 |
| Mar 31, 2023 | 500,000.00 |
| Dec 31, 2022 | 59,000.00 |
| Sep 30, 2022 | 318,000.00 |
| Jun 30, 2022 | 341,000.00 |
| Mar 31, 2022 | 509,000.00 |